Abstract:Background & aims: T helper 1 (Th1) effector cells are implicated in inflammatory bowel disease. The stimulator of interferon genes (STING), an intracellular DNA sensor, has been shown to regulate infection and various cancers. However, whether and how intrinsic STING signaling in Th1 cells regulates colitis is still unknown. Methods: Dextran sodium sulfate-induced colitis and wild-type/STING-deficient CD4+T cell adoptive transfer models were used to analyze the role of STING in regulating colitis. The effect of STING on Th1 cells was determined by flow cytometry, RNA sequencing, metabolic assays, and mitochondrial functions. 16S ribosomal RNA sequencing and germ-free mice were used to investigate whether the microbiota were involved. The in vivo effect of STING agonist in murine colitis was determined. The expression and role of STING in human T cells were also determined. Results: Activation of STING transformed proinflammatory IFNγ+Th1 cells into IL-10+IFNγ+Th1 cells, which were dramatically less pathogenic in inducing colitis. STING promoted Th1 interleukin (IL)-10 production by inducing STAT3 translocation into nuclear and mitochondria, which promoted Blimp1 expression and mitochondrial oxidation, respectively. Blockade of glucose or glutamine-derived oxidation, but not lipid-derived oxidation, suppressed STING induction of IL-10. Gut microbiota were changed in STING-/- mice, but the altered microbiota did not mediate STING effects on intestinal CD4+T cell production of IL-10. Translationally, STING agonists suppressed both acute and chronic colitis. Intestinal STING+ CD4+T cells were increased in inflammatory bowel disease patients, and STING agonists upregulated IL-10 production in human CD4+T cells. Conclusions: These findings establish a crucial role of T cell-intrinsic STING in switching off the pathogenic programs of Th1 cells in intestinal inflammation.

Potential Therapeutic Value of the STING Inhibitors

Progress in innate immunity signaling molecule STING

Post-Translational Modifications of STING: A Potential Therapeutic Target

Agonists and Inhibitors of the STING Pathway: Potential Agents for Immunotherapy

An updated patent review of stimulator of interferon genes agonists (2021 – present)

Multifaceted functions of STING in human health and disease: from molecular mechanism to targeted strategy

Regulating STING in health and disease

Mechanism and effects of STING-IFN-I pathway on nociception: A narrative review.

STING, a promising target for small molecular immune modulator: A review

Targeting STING oligomerization with small-molecule inhibitors

Agonist of stimulator of interferon genes as antitumor agents: a patent review (2008-2020)

IUPHAR ECR review: The cGAS-STING pathway: Novel functions beyond innate immune and emerging therapeutic opportunities

Stimulator of interferon genes (STING): Key therapeutic targets in ischemia/reperfusion injury

Development of small molecule inhibitors/agonists targeting STING for disease

STING inhibitors target the cyclic dinucleotide binding pocket

Design, synthesis, and evaluation of thiazolecarboxamide derivatives as stimulator of interferon gene inhibitors

Advances in the Prerequisite and Consequence of STING Downstream Signalosomes

Intrinsic STING Switches off Pathogenetic Programs of Th1 Cells to Inhibit Colitis

Suppression of systemic autoimmunity by the innate immune adaptor STING

Activation of Stimulation of Interferon Genes (STING) Signal and Cancer Immunotherapy

STING Agonists/Antagonists: Their Potential as Therapeutics and Future Developments